Cheng-Ping Yu
Overview
Explore the profile of Cheng-Ping Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
1225
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wu Y, Ho J, Yu C, Cho C, Wu C, Huang C, et al.
Cancers (Basel)
. 2021 Apr;
13(9).
PMID: 33922395
Gemcitabine (GCB) resistance is a major issue in bladder cancer chemoresistance, but its underlying mechanism has not been determined. Epithelial-mesenchymal transition (EMT) has been shown to be comprehensively involved in...
12.
Lin T, Gao H, Liao G, Yu J, Dai M, Ho J, et al.
Cancers (Basel)
. 2021 Mar;
13(4).
PMID: 33670083
Background: To realize the association between stratified expression levels of ER and PgR and long-term prognosis of breast cancer patients who received adjuvant hormone therapy, this study aimed to propose...
13.
Cho C, Yu C, Wu C, Ho J, Yang C, Yu D
Kaohsiung J Med Sci
. 2020 Dec;
37(2):128-135.
PMID: 33280258
The aim of the study is to investigate the ability of phytochemicals to overcome the multiple drug resistance (MDR) of bladder cancer. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to evaluate...
14.
Huang C, Ho J, Chiang J, Yu C, Yu D
Cells
. 2020 Jun;
9(6).
PMID: 32517366
Exosomes are essential for several tumor progression-related processes, including the epithelial-mesenchymal transition (EMT). Long non-coding RNAs (lncRNAs) comprise a major group of exosomal components and regulate the neoplastic development of...
15.
Yu D, Chen Y, Wu C, Yu C
Int J Clin Exp Pathol
. 2020 Jan;
10(11):11069-11074.
PMID: 31966454
Background: Survey for more accurate biomarkers for predicting and preventing the future recurrence in high risk patients is urgently needed. The transcription factor forkhead box-O3 (FOXO3) is a well-established tumor...
16.
Cho C, Yang C, Wu C, Ho J, Yu C, Wu S, et al.
Oncol Lett
. 2019 Dec;
18(6):6869-6876.
PMID: 31807190
Gemcitabine (GCB), which functions via the inhibition of DNA synthesis, is commonly used in the treatment of bladder cancer; however, its response rate is not satisfactory due to the development...
17.
Fann J, Chang K, Hsu C, Yen A, Yu C, Chen S, et al.
Cancers (Basel)
. 2019 Mar;
11(3).
PMID: 30866499
Elucidating whether and how long-term survival of breast cancer is mainly due to cure after early detection and effective treatment and therapy or overdiagnosis resulting from the widespread use of...
18.
Liu J, Yu C, Chuang H, Wu C, Hsu R
Prostate Cancer Prostatic Dis
. 2019 Jan;
22(3):475-482.
PMID: 30692587
Background: Androgen deprivation therapy (ADT) has been a mainstay of treatment for advanced prostate cancer (PCa), but limited studies have been performed to investigate the association between ADT and autoimmune...
19.
Lin C, Tseng K, Liu J, Chuang H, Lien C, Chen Y, et al.
Int J Environ Res Public Health
. 2018 Nov;
15(11).
PMID: 30469385
Both periodontal disease (PD) and inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are important diseases of the alimentary tract. Microbiome and immune-mediated inflammatory processes play...
20.
Yu C, Tang Y, Cha L, Milikisiyants S, Smirnova T, Smirnov A, et al.
J Am Chem Soc
. 2018 Oct;
140(45):15190-15193.
PMID: 30376630
Installation of olefins into molecules is a key transformation in organic synthesis. The recently discovered decarboxylation-assisted olefination in the biosynthesis of rhabduscin by a mononuclear non-heme iron enzyme ( P.IsnB)...